At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 46 enrolled
Drug / intervention
placebo +2 moredrug
Likely dose
placebo 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome
In Brief
A Phase 4 clinical trial evaluating placebo, Nebivolol, and 1 other intervention for Metabolic Syndrome. Completed, enrolled 46 participants across 1 site.
Detailed Summary
Test the hypothesis that nebivolol treatment improves fibrinolytic balance and insulin sensitivity compared to metoprolol treatment in individuals with metabolic syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedOct 2008
Primary CompletionJun 2011
TodayJul 2026
First PostedOct 20, 2008
Enrollment StartOct 1, 2008
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.7 years ago
Interventions
placebodrug
Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
Nebivololdrug
Nebivolol 5 mg by mouth daily for 12 weeks.
Metoprololdrug
Metoprolol ER 100mg by mouth daily for 12 weeks.